EpiEndo Pharmaceuticals - Reykjavík, Iceland

EpiEndo is a clinical-stage biopharmaceutical company that is pioneering a new way to treat inflammatory disorders. By focusing on strengthening the integrity of epithelial cells, which form a vital protective barrier in human skin, lungs, intestines, and genitalia, EpiEndo is creating a portfolio of orally-available macrolide drug candidates. These first-in-class therapeutics have the potential to reduce the global burden of chronic respiratory diseases and other unmet medical needs. The company's lead drug EP395 is a non-antibiotic macrolide that is intended to be the first of its kind to enter the market, offering both barrier-strengthening and anti-inflammatory benefits to those suffering from COPD and other airway diseases.